To determine the occurrence of extremely low HDL cholesterol ( HDL-C ) among participants in the Action to Control Cardiovascular Risk in Diabetes ( ACCORD ) Lipid Trial and to examine the relationship of this finding with treatment with fenofibrate and thiazolidinedione ( TZD ) .